High-mobility group box 1 is involved in the development of benign prostatic hyperplasia with chronic prostatic inflammation

References

• Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991;338:469–71.
   PubMed Web of Science ®Google Scholar
• Juliao AA, Plata M, Kazzazi A, Bostanci Y, Djavan B. American Urological Association and European Association of Urology guidelines in the management of benign prostatic hypertrophy: revisited. Curr Opin Urol 2012;22:34–9.
   PubMed Web of Science ®Google Scholar
• Moore D. Inflammation of the prostate gland. J Urol 1937;38:173–82.
   Google Scholar
• Nickel JC. Inflammation and benign prostatic hyperplasia. Urol Clin North Am 2008;35:109–15.
   PubMed Web of Science ®Google Scholar
• Kramer G, Mitteregger D, Marberger M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol 2007;51:1202–16.
   PubMed Web of Science ®Google Scholar
• Roehrborn CG. Definition of at-risk patients: baseline variables. BJU Int 2006;97:7–11.
   PubMed Web of Science ®Google Scholar
• Steiner GE, Stix U, Handisurya A, Willheim M, Haitel A, Reithmayr F, et al. Cytokine expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue. Lab Invest 2003;83:1131–46.
   PubMed Web of Science ®Google Scholar
• Bustin M. Revised nomenclature for high mobility group (HMG) chromosomal proteins. Trends Biochem Sci 2001;26:152–3.
   PubMed Web of Science ®Google Scholar
• Czura CJ, Tracey KJ. Targeting high mobility group box 1 as a late acting mediator of inflammation. Crit Care Med 2003;31:S46–50.
   PubMed Web of Science ®Google Scholar
• Degryse B, Bonaldi T, Scaffidi P, Müller S, Resnati M, Sanvito F, et al. The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. J Cell Biol 2001;152:1197–206.
   PubMed Web of Science ®Google Scholar
• Fiuza C, Bustin M, Talwar S, Tropea M, Gerstenberger E, Shelhamer JH, et al. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 2003;101:2652–60.
   PubMed Web of Science ®Google Scholar
• Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999;285:248–51.
   PubMed Web of Science ®Google Scholar
• Ombrellino M, Wang H, Ajemian MS, Talhouk A, Scher LA, Friedman SG, et al. Increased serum concentrations of high-mobility-group protein 1 in haemorrhagic shock. Lancet 1999;354:1446–7.
   PubMed Web of Science ®Google Scholar
• Huttunen HJ, Fages C, Rauvala H. Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J Biol Chem 1999;274:19919–24.
   PubMed Web of Science ®Google Scholar
• Wang H, Vishnubhakat JM, Bloom O, Zhang M, Ombrellino M, Sama A, et al. Proinflammatory cytokines (tumor necrosis factor and interleukin 1) stimulate release of high mobility group protein-1 by pituicytes. Surgery 1999;126:389–92.
   PubMed Web of Science ®Google Scholar
• Han Q, Zhang X, Xue R, Yang H, Zhou Y, Kong X, et al. AMPK potentiates hypertonicity-induced apoptosis by suppressing NFκB/COX-2 in medullary interstitial cells. J Am Soc Nephrol 2011;22:1897–911.
   PubMed Web of Science ®Google Scholar
• Barry MJ, Fowler FJJr, O’Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, et al. The Measurement Committee of the American Urological Association. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol 1992;148:1549–57.
   PubMed Web of Science ®Google Scholar
• Kramer G, Marberger M. Could inflammation be a key component in the progression of benign prostatic hyperplasia? Curr Opin Urol 2006;16:25–9.
   PubMed Web of Science ®Google Scholar
• Nickel JC, Roehrborn CG, O’Leary MP, Bostwick DG, Somerville MC, Rittmaster RS. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol 2008;54:1379–84.
   PubMed Web of Science ®Google Scholar
• Bustin M. Revised nomenclature for high mobility group (HMG) chromosomal proteins. Trends Biochem Sci 2001;26:152–3.
   PubMed Web of Science ®Google Scholar
• Wang C, Fei G, Liu Z, Li Q, Xu Z, Ren T. HMGB1 was a pivotal synergistic effector for CpG oligonucleotide to enhance the progression of human lung cancer cells. Cancer Biol Ther 2012;13:727–36.
   PubMed Web of Science ®Google Scholar
• Rabadi MM, Ghaly T, Goligorksy MS, Ratliff BB. HMGB1 in renal ischemic injury. Am J Physiol Renal Physiol 2012;303:F873–85.
   PubMed Web of Science ®Google Scholar
• Yang D, Chen Q, Yang H, Tracey KJ, Bustin M, Oppenheim JJ. High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin. J Leukoc Biol 2007;81:59–66.
   PubMed Web of Science ®Google Scholar
• Dumitriu IE, Baruah P, Valentinis B, Voll RE, Herrmann M, Nawroth PP, et al. Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J Immunol 2005;174:7506–15.
   PubMed Web of Science ®Google Scholar
• Rouhiainen A, Tumova S, Valmu L, Kalkkinen N, Rauvala H. Pivotal advance: analysis of proinflammatory activity of highly purified eukaryotic recombinant HMGB1 (amphoterin). J Leukoc Biol 2007;81:49–58.
   PubMed Web of Science ®Google Scholar
• Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002;418:191–5.
   PubMed Web of Science ®Google Scholar
• Limana F, Esposito G, D’Arcangelo D, Di Carlo A, Romani S, Melillo G, et al. HMGB1 attenuates cardiac remodeling in the failing heart via enhanced cardiac regeneration and miR-206-mediated inhibition of TIMP-3. PLoS One 2011;6e:19845.
   Google Scholar
• de Souza AW, Westra J, Limburg PC, Bijl M, Kallenberg CG. HMGB1 in vascular diseases: its role in vascular inflammation and atherosclerosis. Autoimmun Rev 2012;11:909–17.
   PubMed Web of Science ®Google Scholar
• Kokkola R, Andersson A, Mullins G, Ostberg T, Treutiger CJ, Arnold B, et al. RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages. Scand J Immunol 2005;61:1–9.
   PubMed Web of Science ®Google Scholar
• Qin YH, Dai SM, Tang GS, Zhang J, Ren D, Wang ZW, et al. HMGB1 enhances the proinflammatory activity of lipopolysaccharide by promoting the phosphorylation of MAPK p38 through receptor for advanced glycation end products. J Immunol 2009;183:6244–50.
   PubMed Web of Science ®Google Scholar
• Luan ZG, Zhang H, Yang PT, Ma XC, Zhang C, Guo RX. HMGB1 activates nuclear factor-κB signaling by RAGE and increases the production of TNF-α in human umbilical vein endothelial cells. Surg Res 2013;180:310–16.
   PubMed Web of Science ®Google Scholar